After reporting in September that it raised $331.6 million of a $375 million venture capital fund, Menlo Park, California-based Longitude Capital announced on 10 October that it closed Longitude Venture Partners II with $385 million to invest in drug development and medical technology.
Longitude Capital co-founder and managing director Patrick Enright told Scrip last month that the fundraising environment for life science-focused venture...





